Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F2IM
|
|||
| Former ID |
DCL001210
|
|||
| Drug Name |
MEDI-573
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
| Company |
MedImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Insulin-like growth factor-I (IGF1) | Target Info | Modulator | [3] |
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | |||
| SHP2 signaling | ||||
| IGF1 pathway | ||||
| Ceramide signaling pathway | ||||
| Integrins in angiogenesis | ||||
| Stabilization and expansion of the E-cadherin adherens junction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7749). | |||
| REF 2 | Clinical pipeline report, company report or official report of MedImmune (2011). | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.